Prior to leading In Vivo, Lucie was a senior editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo online as well as the annual Outlook publication. Covering the biopharma space since 2012, Lucie writes feature articles on the topics of leadership, R&D, innovation and more. She also regularly attends industry events and moderates panel discussions on topics such as investment trends, women’s health and R&D hot topics.
Latest from Lucie Ellis-Taitt
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
King’s College London has released a freely available ‘Human Gut Microbiome Atlas’ to help researchers better understand how microorganisms in the gut impact disease.
King’s College London has released a freely available ‘Human Gut Microbiome Atlas’ to help researchers better understand how microorganisms in the gut impact disease.
Last year, In Vivo spotlighted some of biopharma’s most highly valued yet unpartnered assets. Now it’s time to see if deals have been struck and review how NPVs have changed.
Together, Merck’s heads of oncology and head of digital health outline their cross-functional strategy to enhance care for cancer patients through digital tools.